Merck's efinopegdutide meets primary endpoint in Phase 2b MASH trial
MRK•Merck said its once-weekly injectable efinopegdutide met the primary endpoint in a Phase 2b trial in adults with MASH and moderate-to-advanced liver fibrosis. It improved MASH resolution without worsening liver scarring; adverse-event discontinuations were higher than with placebo.
1. Trial results
Efinopegdutide also improved liver scarring without worsening steatohepatitis. Its safety profile was generally consistent with semaglutide, although treatment discontinuations due to adverse events were higher with efinopegdutide. The results were presented at The Liver Meeting in Denver and published in The Lancet.
